ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2749

Four-Distinct Phenotypes of Patients with Necrotizing Arteritis of Medium and Small Arteries

Tsuyoshi Shirai1, Hiroshi Fujii1, Yoko Fujita2, Yuko Shirota1, Tomonori Ishii1 and Hideo Harigae1, 1Department of Hematology and Rheumatology, Tohoku University Graduate School of Medicine, Sendai, Japan, 2Department of Hematolgy and Rheumatolgy, Tohoku University Graduate School of Medicine, Sendai, Japan

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: Cutaneous manifestations, polyarteritis nodosa and vasculitis

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 7, 2017

Title: Vasculitis Poster III: Other Vasculitis Syndromes

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Polyarteritis nodosa (PAN) is a necrotizing arteritis of medium and small arteries. PAN is divided into systemic and cutaneous PAN (cPAN). cPAN can be further classified into mild cPAN or severe cPAN in which ulcer, necrosis, or neuritis is observed. However, it is sometimes difficult to set a boundary between severe cPAN and systemic PAN, and their optimal treatments are still unclear. The aim of this study is to evaluate clinical characteristics of patients with necrotizing arteritis of medium and small arteries.

Methods: 50 patients who were diagnosed as necrotizing arteritis of medium and small arteries without glomerulonephritis or vasculitis in arterioles, capillaries, or venules during 2008-2016 in our institution were enrolled to this study. Clinical backgrounds, symptoms, laboratory findings including inflammatory markers and antineutrophil cytoplasmic antibodies (ANCA), affected organs, treatments, and the rates of relapse and death were retrospectively evaluated.

Results: Among 50 patients with necrotizing arteritis of medium and small arteries, 39 patients were classified as cPAN (mild, 18; ulcer or necrosis, 8; neuritis, 9; both, 4), and 11 cases manifested systemic vasculitis. One case of cPAN developed renal involvement. Clinical characteristics of mild cPAN included female predominance (94.4%) and younger age (median, 33), while severe cPAN and systemic type had no sex difference. The characteristics of systemic type included older age (median, 69), general symptoms, higher levels of inflammatory markers, lower levels of serum proteins, and organ damages. Severe cPAN manifested intermediate phenotypes. The positivity of autoantibodies in cPAN was about 30 %, while 81.8 % of systemic type possessed some autoantibodies. Particularly, 54.5 % of systemic type possessed myeloperoxidase (MPO)-ANCA though the titers were significantly lower than those of microscopic polyangiitis, suggesting non-specific elevation of MPO-ANCA in Japanese population. The median doses of PSL for mild cPAN, severe cPAN, and systemic type were 20, 40, 40 mg/day, respectively. Immunosuppressants were used in 20% of mild cPAN, 90% of severe cPAN, and 73% of systemic type. Although the mortality rates were indistinguishable, the relapse rates of cPAN with ulcer or necrosis were significantly higher than other types (p=0.0032, figure 1).

Conclusion: 22% of patients with necrotizing arteritis of medium and small arteries presented systemic vasculitis. The clinical characteristics of mild cPAN, cPAN with ulcer or necrosis, cPAN with neuritis, and systemic vasculitis were distinct from each other, suggesting that they should be managed differently. Particularly, cPAN with ulcer or necrosis showed high relapse rates, indicating unmet need to establish adequate treatments such as rituximab. 


Disclosure: T. Shirai, None; H. Fujii, None; Y. Fujita, None; Y. Shirota, None; T. Ishii, Chugai, Ono, Pfizer, Mitsubishi-Tanabe, Astellas, 8; H. Harigae, None.

To cite this abstract in AMA style:

Shirai T, Fujii H, Fujita Y, Shirota Y, Ishii T, Harigae H. Four-Distinct Phenotypes of Patients with Necrotizing Arteritis of Medium and Small Arteries [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/four-distinct-phenotypes-of-patients-with-necrotizing-arteritis-of-medium-and-small-arteries/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/four-distinct-phenotypes-of-patients-with-necrotizing-arteritis-of-medium-and-small-arteries/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology